Project

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

Completed - recruitment paused · 2024 until 2028

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed - recruitment paused
Start Date
2024
End Date
2028
Financing
Industry
Labels
lymphoma
Brief description/objective